The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2023-01-01
-Paragraph 10
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_InvestmentsInJointVentures
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 50
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_a&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_UndrawnBorrowingFacilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amounts payable partners in collaboration agreements.

+ References

No definition available.

+ Details

Name:	sny_AmountsPayablePartnersInCollaborationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Received For Development Costs

+ References

No definition available.

+ Details

Name:	sny_CommitmentsReceivedForDevelopmentCosts
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Related To Maximum Payments For Projects Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commitments Related To Milestone Payments For Projects Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments related to r and d payments contingent upon attainment of sales targets.

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitments Related To Research And Development Relating To Projects In Research Phase

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cumulative Development Costs Incurred

+ References

No definition available.

+ Details

Name:	sny_CumulativeDevelopmentCostsIncurred
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number Of Drug Targets Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfDrugTargetsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Immunology Or Inflammation Targets Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Oncology Targets Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfOncologyTargetsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Therapeutic Targets Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Off-Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments

+ References

No definition available.

+ Details

Name:	sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of cumulative development costs reimbursed.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of future development expense funded by company.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfFutureDevelopmentExpenseFundedByCompany
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of future development expense funded by other party.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of profit share on counter parties profit.

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Provisions and other current and non-current liabilities.

+ References

No definition available.

+ Details

Name:	sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Reserve percentage of pandemic vaccines.

+ References

No definition available.

+ Details

Name:	sny_ReservePercentageOfPandemicVaccines
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Transfer percentage of pandemic vaccines.

+ References

No definition available.

+ Details

Name:	sny_TransferPercentageOfPandemicVaccines
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront payments.

+ References

No definition available.

+ Details

Name:	sny_UpfrontPayments
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	ifrs-full_CategoriesOfRelatedPartiesAxis=sny_WorldHealthOrganizationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_ScribeTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_ProventionBioIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_ExscientiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_IGMBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_AtomwiseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_InsilicoMedicineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_LonzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_BlackstoneLifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_AblynxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_KymabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_ProventionBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Off balance sheet commitments - Additional Information (Details) € in Millions, $ in Millions							3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 04, 2023 EUR (€)	Oct. 04, 2023 USD ($)	Oct. 03, 2023 USD ($)	Jun. 19, 2023 USD ($)	Mar. 15, 2022 EUR (€)	Feb. 27, 2017 EUR (€)	Mar. 31, 2022	Dec. 31, 2022 EUR (€)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Oct. 04, 2023 USD ($)	Apr. 27, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Nov. 08, 2022 target	Aug. 17, 2022 target	Mar. 29, 2022 target	Jan. 07, 2022 molecule	Dec. 31, 2021 EUR (€)	Apr. 08, 2021 USD ($)	Feb. 28, 2014
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to research and development relating to projects in research phase								€ 18,000	€ 16,800	€ 18,000
Commitments related to research and development payments contingent upon attainment of sales targets								18,500	17,900	18,500
Commitments related to collaboration, discovery, development and commercialization agreements								8,800	10,000	8,800
Commitments related to attainment of regulatory and sales milestones for commercialized products								7,600	8,500	7,600
Cumulative development costs incurred									8,600
Total credit facilities								€ 8,000	€ 8,000	€ 8,000								€ 8,000
Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments \| $													$ 300
World Health Organization
Provisions And Other Current And Non-Current Liabilities [Line Items]
Percentage of pandemic vaccines agreed to transfer																				7.50%
Percentage of pandemic vaccines agreed to reserve																				7.50%
Joint ventures
Provisions And Other Current And Non-Current Liabilities [Line Items]
Percentage of future development expense funded by other party						5000.00%
Scribe Therapeutics
Provisions And Other Current And Non-Current Liabilities [Line Items]
Upfront payment \| $				$ 40
Scribe Therapeutics \| Maximum
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to milestone payments for projects under collaboration agreements \| $				$ 1,200
Janssen Pharmaceuticals, Inc
Provisions And Other Current And Non-Current Liabilities [Line Items]
Upfront payment \| $			$ 175
Teva Pharmaceuticals
Provisions And Other Current And Non-Current Liabilities [Line Items]
Upfront payment	€ 469	$ 500
Teva Pharmaceuticals \| Maximum
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to milestone payments for projects under collaboration agreements	€ 940										$ 1,000
Provention Bio, Inc \| Maximum
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to milestone payments for projects under collaboration agreements												€ 946
Exscientia \| Maximum
Provisions And Other Current And Non-Current Liabilities [Line Items]
Number of novel small molecule candidates developed \| molecule																	15
IGM Biosciences, Inc \| Maximum
Provisions And Other Current And Non-Current Liabilities [Line Items]
Number of oncology targets under collaboration agreement \| target																3
Number of immunology or inflammation targets under collaboration agreement \| target																3
Atomwise \| Maximum
Provisions And Other Current And Non-Current Liabilities [Line Items]
Number of drug targets under collaboration agreement \| target															5
Insilico Medicine \| Maximum
Provisions And Other Current And Non-Current Liabilities [Line Items]
Number of therapeutic targets under collaboration agreement \| target														6
Lonza \| Joint ventures
Provisions And Other Current And Non-Current Liabilities [Line Items]
Investments in joint ventures						€ 300
Percentage of future development expense funded by company						50.00%
Amounts payable partners in collaboration agreements						€ 600
Antibodies Collaboration agreement \| Blackstone Life Sciences
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to maximum payments for projects under collaboration agreement					€ 300
Antibodies Collaboration agreement \| Regeneron Pharmaceuticals, INC
Provisions And Other Current And Non-Current Liabilities [Line Items]
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)							10.00%	20.00%
Percentage of cumulative development costs reimbursed									50.00%	50.00%
Commitments received for development costs								€ 2,700	€ 2,100	€ 2,700
Ablynx NV
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to collaboration, discovery, development and commercialization agreements								1,000	900	1,000
Kymab
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to collaboration, discovery, development and commercialization agreements								€ 200	200	€ 200
Commitments related to milestone payments for projects under collaboration agreements \| $																			$ 350
Provention Bio
Provisions And Other Current And Non-Current Liabilities [Line Items]
Commitments related to collaboration, discovery, development and commercialization agreements									€ 300